. Author manuscript; available in PMC: 2008 Aug 1.

Published in final edited form as: Am J Physiol Lung Cell Mol Physiol. 2007 Apr 13;293(2):L281–L289. doi: 10.1152/AJPLUNG.00458.2006

Table 2.

Effect of protein kinase C inhibition on terbutaline-sensitive alveolar fluid clearance at day 2 after RSV infection.

Treatment	Conc.	n^*	% AFC₃₀^†	Δ_TERBUT (%)^‡
None	-	10	21.8 ± 2.3	-
Terbutaline	100μM	17	24 ± 2.3	10
PKC inhibitor (GF109203X)	100μM	6	19.7 ± 1.9	-
GF109203X + Terbutaline	100μM + 100μM	7	33.7 ± 2.1 ^§^#	54
PKC_α/β1 inhibitor (Gö6976)	10μM	9	19.8 ± 2.5	-
Gö6976 + Terbutaline	10μM + 100μM	11	23.8 ± 2.5	8
Myristoylated PKCζ inhibitor (mPKCζi)	2μg/ml	8	23.2 ± 2	-
mPKCζi + Terbutaline	2μg/ml + 100μM	8	33.3 ± 1.1^**	52
Unmyristoylated PKCζ inhibitor + Terb.	2μg/ml + 100μM	6	23.8 ± 1.3	9

Number of mice in which AFC was evaluated

^†

Mean % AFC ± SEM

^‡

% change in mean AFC with terbutaline

^§

% AFC₃₀ in mock-infected mice is 34.8 ± 1.5 (n=11) (from ref. 4)

P<0.05,

^**

P<0.005 versus untreated AFC at day 2